Share Name Share Symbol Market Type Share ISIN Share Description
Shire Plc LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -106.50p -2.75% 3,764.50p 3,775.00p 3,776.50p 3,842.50p 3,738.50p 3,840.00p 3,335,147 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9,229.1 393.7 34.8 112.7 22,309.32

Shire Share Discussion Threads

Showing 2201 to 2223 of 2225 messages
Chat Pages: 89  88  87  86  85  84  83  82  81  80  79  78  Older
DateSubjectAuthorDiscuss
19/8/2017
12:27
My portfolio is probably more defensive but still lost 3-4% in past 2 weeks largely due to Hikma and Shire. I have all 3 water utilities, NG, CNA, SSE. AZN, GSK, VEC, HIK, SHP so a lot of pharma. VEC has a great balance sheet BTW. No debt and 100M cash. DEB, KGF so some retail RDSB MTC, TPG, DOM
justiceforthemany
19/8/2017
00:05
justice , yes pretty defensive... couple of big xd's this week as well with BATS and IMB current holdings.. LON:ABF LON:BATS LON:BRBY LON:BVIC LON:DOM LON:ECM LON:GRG LON:GNK LON:GSK LON:HILS LON:IMB LON:KIE LON:MERL LON:MKS LON:SHP LON:SSPG LON:TSCO
philanderer
18/8/2017
21:21
As for brutal have a look at Hikma. 2300p to 1100p in 5 months on the back of no profit warning just the loss of one potential inhaler! Now trading just above book value. Crazy.
justiceforthemany
18/8/2017
21:18
As for Shire a pathetic mini rally fizzled into new lows. In the US $144 may be the bottom. It has bounced a little off this. $144 was a key support level not seen since April 2014. 3 and a half year lows
justiceforthemany
18/8/2017
19:30
How have you done that again? A lot of defensives? Even my water and utility stocks got hammered past 2 days. Hikma has been a disaster.
justiceforthemany
18/8/2017
17:16
That's as though the last seven days never happened . My portfolio is almost exactly unchanged from last friday's close :-O Good weekend all.
philanderer
18/8/2017
16:09
Fingers crossed that 3500p is the floor. That's been pretty brutal down from 5000p in 6 months :-S
philanderer
18/8/2017
15:23
As I said before, someone wants this down low, and who are we to complain. If they want to have a hissy fit with Shire management team and practically give shares away at £36, I'll be more than happy to oblige. Regarding negative reaction to the "split" possibility. Comparison with the reverse situation with GSK being punished for NOT splitting are beyond ironic. Fact is Shire could spin off Neuro and investors would be left holding two companies both worth more than they were when combined in one firm. Analysts spent years fingering ADHD drugs as "controversial" and a "risk". Now the same analysts are frothing at the mouth at the mere suggestion from Shire that it would carefully review a spin off of Neuro IF IT WOULD GENERATE MORE VALUE FOR INVESTORS.
romeike
18/8/2017
15:13
Profit warnings dont get this type of treatment
bigboots
18/8/2017
14:02
The Alphaville article clarifies things quite nicely,so I'll summarise.I don't quite know who this commentator is,broker probably.What they're saying is that investors have their doubts about a possible splitting of the group and in certain key areas there's increasing competition but ultimately "Shire remains the cheapest stock in our sector,trading at 9.8x PE (37%discount to peers) and 10.2x EV/EBITDA (20% discount to peers)."The target price has been cut but remains at £47. "Concerns are as detailed in the past,haemo competition,ADHD spinoff destroying rather than adding value,pricing pressure on branded across the board..." Catalysts for downgrades comes from Roche's ACE910 P3 data which was well received by physicians at ISTH last month.CSL has launched Haegarda at a competitive price.This has triggered cuts in forecasts for Shire's non-inhibitor haemophilia and HAE franchises resulting in cuts of 15-20% to 2018-22 EPS forecasts. Commentator expects "sentiment headwinds will persist until year end".They cite competitive pressures from the launch of CSL's Haegarda and HAVEN 3 data/ US approval.However,they consider negative factors to be discounted with the price under £40 and the ADRs under $150.Positive influences include a decision on the future of Neuroscience,new drug approvals (SHP643,Xildra ex-US) continued strong cash flow,debt pay down and clarification of the extent of competitive threats.
steeplejack
18/8/2017
13:48
'World Stocks Tumble as Market Hopes in Trump’s Reform Agenda Fade' HTTP://fortune.com/2017/08/18/world-stocks-fall-trump-agenda/
philanderer
18/8/2017
13:27
Comment on FT Alphaville... HTTPS://ftalphaville.ft.com/marketslive/2017-08-18/
philanderer
18/8/2017
11:46
I've been lucky with this share always made a profit on it . Last deal I bought at 4250 and sold same day at nearly 4400 on the day of their results. I can only think its trending downwards because of the threat to spin off part of the company and the unknown or someone knows about a possible takeover bid. With no SD it is a bit easier to daily or swing trade on this share if you get the timing right. Think it's going 3500 then the shorts might jump in . What's everyone's view ?
jonesy196
18/8/2017
11:46
I'll be waiting for £36
romeike
18/8/2017
10:11
how are people quoting p/e as low as 10? am i missing something edit: must be referring to forward p/e. makes sense. apologies
swedeee
18/8/2017
10:02
QP. Safe haven and also GLEN
a2584728
18/8/2017
09:53
Sold a small amount at 38.12 yesterday, added back.
essentialinvestor
18/8/2017
09:48
Twa@tted this morning. All mine down bar ECM :-s
philanderer
18/8/2017
00:00
And even lower tonight in the USA.
philanderer
18/8/2017
00:00
And even lower tonight in the USA.
philanderer
17/8/2017
20:40
Late sell off again...
ruethewhirl
17/8/2017
17:30
I bought a few more today - a while since I'd previously bought any of my previous three tranches and around the same share price, however its about 3 turns lower current year PE. Without wanting to tempt fate, this feel stupidly cheap at the moment
adamb1978
17/8/2017
15:40
17th august Goldman Sachs 'conviction buy' tp 6000p cut from 6400p
philanderer
Chat Pages: 89  88  87  86  85  84  83  82  81  80  79  78  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170820 15:36:39